Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Pharmocokinetic (PK)-Directed High Dose Intravenous Busulfan, Cyclophosphamide and Etoposide Produces Predictable Drug Exposure and Durable Long Term Survival In Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Hongzheng Zhang, Michael Graiser, Donald Hutcherson, M. Olufemi Dada, Stephanie McMillan, BSN, RN, OCN, Ali Zahir, Christopher R Flowers, MD, MS, Edmund Waller

Blood (2010) 116 (21): 1359.

https://doi.org/10.1182/blood.V116.21.1359.1359

Published: 2010

Journal Articles

Rifaximin for Preventing Acute Graft Versus Host Disease: Impact On Plasma Markers of Inflammation and T Cell Activation.

Muna Qayed, MD, Amelia Langston, MD, Kuang-Yueh Chiang, MD, PhD, Joseph Hilinski, MD, Conrad Cole, MD, MSc, Stephanie McMillan, RN, Pamela Rowland, RN, MS, CPNP, Andre Rogatko, PhD, John Horan, MD, MPH

Blood (2009) 114 (22): 4664.

https://doi.org/10.1182/blood.V114.22.4664.4664

Published: 2009

Journal Articles

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

Sagar Lonial, MD, Jonathan Kaufman, MD, Claire Torre, Amelia Langston, Mary J. Lechowicz, Christopher Flowers, Stephanie McMillan, Heather Renfroe, Leonard T Heffner, Edmund K Waller

Blood (2008) 112 (11): 3332.

https://doi.org/10.1182/blood.V112.11.3332.3332

Published: 2008

Journal Articles

Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study

Amelia A Langston, MD, Sujatha Murali, MD, Stephanie McMillan, RN, Leonard T. Heffner, MD, Sagar Lonial, MD, Edmund K. Waller, MD, PhD, Christopher R. Flowers, MD, Jonathan Kaufman, MD, Morgan L. McLemore, MD, Rajni Sinha, MD, Mary J Lechowicz, MD, H. Jean Khoury, MD, Elliott F. Winton, MD

Blood (2008) 112 (11): 3644.

https://doi.org/10.1182/blood.V112.11.3644.3644

Published: 2008

Journal Articles

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

Sagar Lonial, MD, Jonathan Kaufman, MD, Amelia A. Langston, MD, Leonard T. Heffner, MD, Claire Torre, Mary J. Lechowicz, MD, Christopher Flowers, MD, Stephanie McMillan, RN, Michael Arnold, Ned K. Waller, MD, PhD

Blood (2007) 110 (11): 949.

https://doi.org/10.1182/blood.V110.11.949.949

Published: 2007

Journal Articles

Tolerability and Anti-Leukemic Activity of Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] in Advanced MDS and AML: Interim Analysis of Phase I/II Data.

Sujatha Murali, MD, Elliott F. Winton, MD, Stephanie McMillan, RN, Sagar Lonial, MD, Ned Waller, MD, Leonard Heffner, MD, Christopher Flowers, MD, Jonathan L. Kaufman, MD, Mary Jo Lechowicz, MD, H. Jean Khoury, MD, Amelia Langston, MD

Blood (2006) 108 (11): 1960.

https://doi.org/10.1182/blood.V108.11.1960.1960

Published: 2006

Journal Articles

A Randomized Trial To Evaluate the Impact of Cytokines (G-CSF or GM + G-CSF) on Dendritic Cell and T-Cell Content and Function When Mobilizing Normal Donors for Allogeneic Progenitor Cell Transplant.

Sagar Lonial, MD, Stephanie McMillan, Claire Torre, Amelia A. Langston, MD, Ellie Hamilton, Amanda Cook, Christopher Flowers, MD, Jonathan L. Kaufman, MD, Mary Jo Lechowicz, MD, Ned Waller, MD

Blood (2006) 108 (11): 3377.

https://doi.org/10.1182/blood.V108.11.3377.3377

Published: 2006

Journal Articles

A Randomized Trial To Evaluate the Impact of Cytokines (G-CSF or GM + G-CSF) on Dendritic Cell and T-Cell Content and Function When Mobilizing Normal Donors for Allogeneic Progenitor Cell Transplant.

Sagar Lonial, MD, Claire Torre, Amelia A. Langston, MD, Stephanie McMillan, Ellie Hamilton, Christopher Flowers, MD, Mary J. Lechowicz, MD, Edmund K. Waller, MD, PhD

Blood (2005) 106 (11): 1960.

https://doi.org/10.1182/blood.V106.11.1960.1960

Published: 2005

Journal Articles

A Randomized Trial to Evaluate the Impact of Cytokines on Dendritic Cell, T-Cell and T-Cell Function When Mobilizing Normal Donors for Allogeneic Progenitor Cell Transplant: An Interim Analysis.

Sagar Lonial, MD, Claire Torre, Michelle Hicks, Stephanie Mcmillan, Amelia A. Langston, MD, Christopher R. Flowers, MD, Mary J. Lechowicz, MD, Edmund K. Waller, MD, PhD

Blood (2004) 104 (11): 2854.

https://doi.org/10.1182/blood.V104.11.2854.2854

Published: 2004

Journal Articles

A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg®) for Advanced MDS and Secondary or Relapsed AML.

Amelia A. Langston, MD, Stephanie McMillan, RN, Sagar Lonial, MD, Kenneth Smith, MD, Edmund K. Waller, MD, PhD, Leonard T. Heffner, MD, Silvana Bucur, MD, Istvan Redei, MD, Christopher Flowers, MD, Mary J. Lechowicz, MD, Elliot Winton, MD

Blood (2004) 104 (11): 1814.

https://doi.org/10.1182/blood.V104.11.1814.1814

Published: 2004

NARROW

Pharmocokinetic (PK)-Directed High Dose Intravenous Busulfan, Cyclophosphamide and Etoposide Produces Predictable Drug Exposure and Durable Long Term Survival In Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Rifaximin for Preventing Acute Graft Versus Host Disease: Impact On Plasma Markers of Inflammation and T Cell Activation.

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

Tolerability and Anti-Leukemic Activity of Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] in Advanced MDS and AML: Interim Analysis of Phase I/II Data.

A Randomized Trial To Evaluate the Impact of Cytokines (G-CSF or GM + G-CSF) on Dendritic Cell and T-Cell Content and Function When Mobilizing Normal Donors for Allogeneic Progenitor Cell Transplant.

A Randomized Trial To Evaluate the Impact of Cytokines (G-CSF or GM + G-CSF) on Dendritic Cell and T-Cell Content and Function When Mobilizing Normal Donors for Allogeneic Progenitor Cell Transplant.

A Randomized Trial to Evaluate the Impact of Cytokines on Dendritic Cell, T-Cell and T-Cell Function When Mobilizing Normal Donors for Allogeneic Progenitor Cell Transplant: An Interim Analysis.

A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg®) for Advanced MDS and Secondary or Relapsed AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only